Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Addition eligibility criteria based on tumor type apply Inclusion Criteria: * Ability to provide written informed consent in accordance with federal, local, and institutional guidelines * Histological or cytological diagnosis of metastatic cancer or locally advanced cancer that is not amenable to local therapy * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 * Life Expectancy of at least 3 months * Adequate hepatic, renal, cardiac, and hematologic function * Measurable disease by Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria * Resolution of treatment-related toxicities except alopecia Exclusion Criteria: * Unable to receive oral medications * Unable to receive oral or intravenous (IV) hydration * Intolerance to prior anti-PD-1/PD-L1 therapy * Prior severe hypersensitivity reaction to another monoclonal antibody (mAb) * Any other current or previous malignancy within 3 years except protocol allowed malignancies * Chemotherapy, TKI therapy, radiation therapy or hormonal therapy within 2 weeks * Immunotherapy or biological therapy, or investigational agent within 3 weeks (Note: Some cohort exceptions allow anti-PD-1 therapy) * Active known or suspected exclusionary autoimmune disease * Any condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) or other systemic immunosuppressive medications within 2 weeks * History of known risks factors for bowel perforation * Symptomatic ascites …